drugset / Trial / NCT05773326
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Phase 0
Terminated
5 enrolled
Nader Sanai
Barrow Neurological Institute · collabIvy Brain Tumor Center · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway. Eligible participants will be administered a single infusion of temsirolimus through super-selective intra-arterial infusion or intravenous infusion. Participants will receive the study drug administration on the same day as the planned surgical resection of the tumor.
Timeline
- Start
- 2023-05-15
- Primary completion
- 2025-02-28
- Completion
- 2025-10-16
Outcome
Outcome not reported
Stopped: “Study terminated due to unavailability of the investigational product required to continue the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temsirolimus | Small molecule | — | Other |